Loading organizations...
§ Venture Capital · 25 Northmoor Road, Oxford, United Kingdom, OX2 6UR
Angel investment syndicate facilitating investments and attracting growth capital for early-stage life sciences companies.
Arrowfield Capital is an Oxford-based angel syndicate specializing in early-stage investments within the life sciences sector. The firm provides capital and strategic support to emerging companies, fostering innovative ideas from pre-seed onwards. It identifies and nurtures promising ventures, accelerating novel technologies and therapies, thereby building a portfolio of future healthcare and biotechnology advancements.
David Ford has been a pivotal figure managing the syndicate since 2016. His passion for early-stage investing and insight into foundational support for nascent life sciences companies shaped the firm's strategic direction. Ford's extensive experience guides Arrowfield Capital's commitment to fostering scientific innovation, acknowledging the unique challenges of developing breakthrough concepts. Andrew Martin is also associated.
Arrowfield Capital primarily serves entrepreneurs and scientists developing groundbreaking concepts in life sciences. The firm acts as a crucial early partner, enabling businesses to translate discoveries into commercial realities. Its long-term vision focuses on cultivating a thriving ecosystem for life sciences innovation, ultimately bringing impactful new solutions to market.
Arrowfield Capital has 1 tracked investment across 1 company. The latest tracked deal is $7.0M Seed in PharmEnable in May 2023.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| May 1, 2023 | PharmEnable | $7.0M Seed | — | MP Healthcare Venture Management, Damien Lane, Jonathan Milner, Keith Blundy, Heyford Trust, Martlet Capital, O2H Ventures, Parkwalk Advisors, University OF Cambridge, Wren Capital |